glp 1 drugs and mental health Can diabetes like Ozempic tackle the crisis? Evaluating Glucagon-Like Peptide-1 Receptor Agonists

Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response

& Reddi, A

Total actuations in 3.0 mL = 30

Hirosue, S

The Diabetes Control and Complications Trial research group previously observed that early worsening of diabetic retinopathy can occur with intensive glycemic control, though effective glycemic control ultimately lowers retinopathy risk over the long-term

Trial evidence: Tesamorelin 2mg SC daily sustained GH/IGF-1 elevation, 15-18% visceral fat reduction over 6 months (Falutz, NEJM 2007, PMID 17699044) Ipamorelin 200-300 mcg peak GH 5-10x baseline within 30 minutes, no cortisol/prolactin bump (Raun, EJE 1998, PMID 9539826) GHRH + GHRP synergy 2-3x greater amplitude than either alone (Bowers, JCEM 1991, PMID 2004615) Community protocols extend this evidence base with cycling patterns that weren't studied in the original trials the 5-on/2-off rhythm and 8-week cycles are empirical community consensus, not clinically validated